The problem for BLT is the time line and cost profile to move this from mice to humans is HUGE, both in terms of number of years to get through the multiple FDA (or whatever country you choose) obstacles and the cost to do so.
Reality its an interesting and potentially great product but timeline and cost to fund the timeline mean it is best within a multinational's portfolio not a tiny AU companies, especially one with less than 1 year of funding.
- Forums
- ASX - By Stock
- Ann: EFFICACY IN TRANSPLANT REJECTION
The problem for BLT is the time line and cost profile to move...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online